Loading company…
Neoantigen researches and develops personalized tumor vaccines and neoantigen-based immunotherapies.
Founded in 2016 and based in Hangzhou, China, Neoantigen develops personalized tumor vaccines and other neoantigen-based immunotherapies. Its platform includes AI-based identification and optimization, in vitro verification, and personalized peptide drug preparation and quality control. The company partners with Innovent, Virogin Biotech and Zhejiang University, and planned to use 2021 funding for clinical trials.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in